Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th
- None.
- None.
The pre-clinical results of Telomir Pharmaceuticals' lead product, Telomir-1, suggest a potential breakthrough in the field of age-related disease treatment. By targeting the elongation of telomeres, the company is tapping into a critical aspect of cellular aging. Telomeres, the protective caps at the ends of chromosomes, naturally shorten as cells divide and their length is a biomarker of cellular aging. The ability to elongate these telomeres could theoretically delay senescence, the process that leads to the deterioration of cell function.
From a medical research perspective, the implications are significant. If Telomir-1 can indeed stimulate stem cell renewal and treat conditions like osteoarthritis, it would mark a substantial advancement in regenerative medicine. However, it is essential to approach these results with cautious optimism. The transition from pre-clinical to clinical efficacy is fraught with challenges and many compounds fail to demonstrate the same promise in humans as they do in cell lines. Furthermore, the long-term effects of artificially elongating telomeres are not yet fully understood and could pose unforeseen risks.
Investors in the biotechnology sector pay close attention to pre-clinical trial results, such as those reported by Telomir Pharmaceuticals, because they can significantly impact a company's valuation. The positive results surrounding Telomir-1 have the potential to generate investor interest and raise the stock's profile. However, it is important to note that the company is still in the pre-clinical stage and the road to commercialization is long and uncertain. The costs of advancing to clinical trials can be substantial and there is no guarantee of a successful outcome.
Moreover, the market for anti-aging treatments is both highly lucrative and extremely competitive. A successful entry by Telomir-1 could capture a significant share of this market, but until more definitive clinical data is available, the financial implications remain speculative. Investors should monitor subsequent trial phases closely, as these will provide more concrete evidence of the drug's potential and its impact on Telomir's financial future.
The journey from pre-clinical research to a marketable pharmaceutical product is heavily regulated to ensure safety and efficacy. For Telomir-1 to reach the market, it must pass through a series of clinical trials and receive approval from regulatory bodies such as the FDA. The process is designed to protect patients from potential adverse effects and to ensure that any marketed drug provides the claimed benefits.
While the pre-clinical data is promising, Telomir Pharmaceuticals will need to demonstrate consistent results in human trials. Regulatory bodies will scrutinize the data for statistical significance, safety and the balance of risks versus benefits. Given the novelty of telomere extension as a therapeutic approach, the regulatory pathway may be particularly stringent. The company must be prepared for a rigorous examination of their data and possibly additional studies to explore long-term effects and potential risks associated with telomere elongation.
Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells
The New York Times reports telomere shortening a major contributor to aging
BALTIMORE, March 22, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially address age-related conditions, today announced that Telomir and Danielle R. Baker, Ph.D., of Frontage Laboratories will present a scientific poster presentation at the Global Longevity Federation Conference in Las Vegas on March 26th at 2 pm EDT. The poster will present new data regarding the effect of Telomir-1 on telomere length in three human cell lines.
The basic theory behind Telomir’s research is the concept that elongating telomeres, which are repetitive DNA sequences at the end of chromosomes that protect chromosomes from becoming frayed or tangled, could result in stimulating stem cell renewal and thus the treatment of age-related conditions like osteoarthritis.
This presentation builds on the data that was presented at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024 in February. The poster, titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,” will be presented by Dr. Baker and will include new data that further demonstrates that total telomere length was augmented following various Telomir-1 treatments, supporting the hypothesis that Telomir-1 elongates telomeres.
Telomir believes this research is important and timely as society looks to deal with the challenges associated with aging. As reported in a March 20, 2024, article in The New York Times, titled “Why Do We Age?,” “as we age, telomere shortening becomes a problem, particularly in stem cells, which the body uses to replenish skin, blood and other tissue.” Telomir is working to develop and commercialize Telomir-1 which it believes will elongate telomeres and potentially reversing age-related conditions.
“Presenting our poster at the Global Longevity Federation conference offers a significant opportunity for our team to showcase the potential for Telomir-1. Our poster will include new data that demonstrates the results we have had with our lead development product which supports that Telomir-1 may potentially treat age-related conditions and prolong human life,” stated Chris Chapman, MD, Co-founder, Chairman, Chief Executive Officer and President of Telomir Pharmaceuticals.
“Our pre-clinical results thus far have been extremely encouraging and by presenting our data at the conference we are putting ourselves at the forefront of the longevity community.” Dr. Michael Roizen, Special Advisor to Telomir Pharmaceuticals, added, “As we continue to present new and promising data, we are becoming increasingly enthusiastic about the opportunity that Telomir-1 may have in combating the diseases of aging. With the prospect for additional studies with Telomir-1 in the near future, we are optimistic that we will continue to provide encouraging insights to the longevity and aging community.”
Stephen Gacheru, Vice President, cell & gene therapy operations BGCT at Frontage Laboratories, added, “The team is elated to contribute to the revelation that Telomir-1 modulates telomerase activity, leading to the extension of telomeres. This discovery unveils Telomir-1's steadfast promise in aging and the therapeutic intervention of telomere-associated diseases."
The conference will be hosted by the Academy for Health and Lifespan Research, a distinguished entity devoted to targeting aging as a root cause of all age-related disorders, supporting basic and translational research, while driving change and educating the public. Through research and strategic implementations, the Academy strives to expedite collaboration between top scientists, laboratories, academic institutions and drug companies in order to realize breakthroughs in longevity research and be accessible to all.
To be added to the Telomir Pharmaceuticals email distribution list, please email telomir@kcsa.com with TELO in the subject line.
About Telomir Pharmaceuticals, Inc.
Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps in order to potentially reverse age-related conditions. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents us with an increased chance of contracting a number of degenerative and age-related diseases. Telomir’s goal is to develop and commercialize Telomir-1 (which is proposed to be dosed orally) for hemochromatosis (iron overload) and ultimately post-chemotherapy recovery and a broader range of other age-related inflammatory conditions such as osteoarthritis.
Individuals with elongated telomeres eat healthier, meditate, participate in more social activities with friends, exercise moderately, have sex regularly, and sleep 6-8 hours a night.
The Nobel Assembly at Karolinska Institute (Sweden) awarded the Nobel Prize in Physiology or Medicine in 2009 for the discovery of how chromosomes are protected by telomeres and the enzyme telomerase.
Cautionary Note Regarding Forward-Looking Statements
This press release and the statements of the Company’s management related thereto contains “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding Telomir’s technologies potential in reversing age-related decline and TELOMIR-1’s ability to result in an individual’s ability to repair oneself by using TELOMIR-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties (many of which are beyond the Company’s control) that could cause actual results (including the anticipated benefits of the pre-clinical data discussed herein) to differ materially and adversely from those set forth in or implied by such forward-looking statements. These and other risks concerning Telomir's programs and operations are described in additional detail in its registration statement on Form S-1 and other SEC filings, which are on file with the SEC at www.sec.gov and the Company’s website at https://ir.telomirpharma.com. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.
For further information, please contact:
KCSA Strategic Communications
Phil Carlson
telomir@kcsa.com
Telomir Pharmaceuticals
info@Telomirpharma.com
(813) 864-2558
FAQ
What is the focus of Telomir Pharmaceuticals' lead development product Telomir-1?
Where will Telomir Pharmaceuticals present new data on Telomir-1?
Who will present the scientific poster at the conference?
What does the poster presentation focus on?
What is the basic theory behind Telomir's research?
